|
Synonyms: anti-B7H1 monoclonal antibody | Imfinzi® | MEDI-4736 | MEDI4736
durvalumab is an approved drug (FDA (2017), EMA (2018))
Compound class:
Antibody
Comment: Durvalumab is a monoclonal antibody directed against programmed death-1 ligand-1 (PD-L1, aka CD274), an important immunopharmacological drug discovery target in immuno-oncology.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. A patent search suggests that the development and use of durvalumab may be covered by patent WO2011066389 [2], although we cannot verify this by peptide sequence matches as no sequences from this patent are pulled in a protein BLAST with the light or heavy variable regions of durvalumab peptide sequences. An X-ray crystal structure of the PD-L1/durvalumab complex has been submitted to the RCSB PDB (accession 5X8M) [1]. |
| No information available. |
Summary of Clinical Use  |
| Durvalumab (MEDI-4736) was 'fast tracked' to Phase 3 clinical trial, then receiving full FDA approval in May 2017 for the treatment of advanced/metastatic bladder cancer (urothelial carcinoma) in patients who have already received platinum-containing chemotherapy. In February 2018 FDA approval was expanded to include treatment of some stage III non-small cell lung cancer (NSCLC) patients. It is hoped that durvalumab may show clinical efficacy against other cancers. Click here to link to ClinicalTrials.gov's list of Phase 2 and 3 studies evaluating MEDI-4736 in additional cancer types. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Anti-PD-L1 antibodies interfere with PD-L1 signalling, which results in the activation of tumour-detecting/infiltrating T cells. The drug’s mechanism of action enables the immune cells to detect and destroy tumour cells. |
| External links |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |
